GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » PS Ratio

Xenetic Biosciences (Xenetic Biosciences) PS Ratio : 2.48 (As of Jun. 04, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Xenetic Biosciences's share price is $3.95. Xenetic Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.60. Hence, Xenetic Biosciences's PS Ratio for today is 2.48.

The historical rank and industry rank for Xenetic Biosciences's PS Ratio or its related term are showing as below:

XBIO' s PS Ratio Range Over the Past 10 Years
Min: 0.1   Med: 12.06   Max: 4957.45
Current: 2.47

During the past 13 years, Xenetic Biosciences's highest PS Ratio was 4957.45. The lowest was 0.10. And the median was 12.06.

XBIO's PS Ratio is ranked better than
81% of 1000 companies
in the Biotechnology industry
Industry Median: 9.22 vs XBIO: 2.47

Xenetic Biosciences's Revenue per Sharefor the three months ended in Mar. 2024 was $0.33. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.60.

During the past 12 months, the average Revenue per Share Growth Rate of Xenetic Biosciences was 22.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 34.40% per year.

During the past 13 years, Xenetic Biosciences's highest 3-Year average Revenue per Share Growth Rate was 171.40% per year. The lowest was -89.30% per year. And the median was 14.40% per year.

Back to Basics: PS Ratio


Xenetic Biosciences PS Ratio Historical Data

The historical data trend for Xenetic Biosciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences PS Ratio Chart

Xenetic Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.00 29.82 11.43 2.38 2.08

Xenetic Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 2.28 3.17 2.08 2.36

Competitive Comparison of Xenetic Biosciences's PS Ratio

For the Biotechnology subindustry, Xenetic Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's PS Ratio falls into.



Xenetic Biosciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Xenetic Biosciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.95/1.595
=2.48

Xenetic Biosciences's Share Price of today is $3.95.
Xenetic Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.60.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Xenetic Biosciences  (NAS:XBIO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Xenetic Biosciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences (Xenetic Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110